• ProtoKinetix posted a net loss of $393,650 in fiscal 2025, widening 8.09% from the prior year.
• No revenue was recorded, leaving operating loss at $393,650 versus 2024.
• Professional fees climbed 22.66% to $177,610, driven by legal work on authorized-share voting and a patent-portfolio valuation report.
• Research and development spending rose 7.01% to $106,613 on higher molecule-inventory storage fees.
• Year-end cash totaled $1,118; working capital deficit widened to $183,266, with plans to fund operations through common-stock sales.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. ProtoKinetix Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001079973-26-001218), on September 03, 2026, and is solely responsible for the information contained therein.